Vera Therapeutics, Inc. is a late stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate atacicept is a human TACI Fc fusion protein that binds both BAFF and APRIL cytokines and is administered as a once weekly subcutaneous injection. The company is conducting the pivotal Phase 3 trial ORIGIN 3 for atacicept in immunoglobulin A nephropathy, which met the primary endpoint in June 2025 and led to a Biologics License Application submission to the FDA in November 2025. In ORIGIN 3, atacicept achieved a 46% reduction from baseline in urine protein-to-creatinine ratio and a statistically significant 42% reduction compared to placebo. The FDA granted priority review to the application and set a PDUFA target action date of July 7 2026. Beyond immunoglobulin A nephropathy, Vera Therapeutics is evaluating atacicept in other autoimmune kidney diseases such as primary membranous nephropathy, focal segmental glomerulosclerosis and minimal change disease through the PIONEER phase 2 basket trial. The company also holds worldwide rights to VT-109, a preclinical dual BAFF/APRIL inhibitor for B cell mediated diseases, and to MAU868, a monoclonal antibody for BK virus infection in kidney transplant recipients. The company has received orphan drug designation for atacicept in the European Union and Japan and is seeking the same designation in the United States.

Vera Therapeutics, Inc. has not reported any product revenue to date. The company finances its research and development activities through equity offerings and debt financing. The net proceeds from these financings have been used to advance clinical trials and support operational infrastructure.

Vera Therapeutics, Inc. positions itself as a developer of first in class dual inhibitors of BAFF and APRIL for immunoglobulin A nephropathy and other autoimmune conditions. Its lead candidate atacicept competes with approved agents such as budesonide, sparsentan, iptacopan and sibeprenlimab in the immunoglobulin A nephropathy market. The company estimates the global annual market opportunity for novel disease modifying therapies in immunoglobulin A nephropathy to be between $6 billion and $10 billion. Epidemiology estimates indicate approximately 160,000 biopsy confirmed immunoglobulin A nephropathy patients in the United States, 136,000 in Europe and 130,000 in Japan at peak year. Additional indications under investigation include primary membranous nephropathy affecting about 50,000 patients in the United States, focal segmental glomerulosclerosis affecting about 44,000 patients in the United States and minimal change disease affecting approximately 15,000 adult and 10,000 pediatric patients in the United States. Competitors in the broader autoimmune space include companies developing B cell modulators, complement inhibitors and endothelin receptor antagonists, but atacicept’s dual mechanism and subcutaneous administration differentiate it from existing therapies. The company’s advantage lies in atacicept’s mechanism of blocking both BAFF and APRIL, its favorable safety profile observed across more than 1,900 patient exposures and its potential to modify disease course by reducing galactose deficient IgA1 and stabilizing kidney function. The safety profile of atacicept has been consistent with placebo in clinical trials, showing no signals of immunosuppression or serious infection.

Vera Therapeutics, Inc. serves patients with immunoglobulin A nephropathy, other autoimmune kidney diseases such as primary membranous nephropathy, focal segmental glomerulosclerosis and minimal change disease, and kidney transplant recipients at risk of BK virus infection. In the United States, the company estimates there are about 160,000 diagnosed immunoglobulin A nephropathy patients, 50,000 with primary membranous nephropathy, 44,000 with focal segmental glomerulosclerosis and 25,000 with minimal change disease. For BK virus, approximately 80,000 kidney transplants occur worldwide each year with about 20,000 in the United States and roughly 15% of recipients developing BK viremia. Approximately 3% to 4% of kidney transplant recipients develop BK virus associated nephropathy. The company plans to develop its products for patients in North America, Europe and Asia.